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Poor control of mineral metabolism is independently
associated with mortality in patients receiving hemodialysis.
We analyzed data from a 12-month, prospective,
non-randomized, controlled study of daily hemodialysis
(DHD) (six sessions/week 3 h each) (n¼ 26) vs conventional
hemodialysis (CHD) (three sessions/week 4 h each) (n¼ 51)
for achievement of mineral metabolism goals and we
performed a substudy of weekly dialytic phosphorus removal
in DHD vs CHD. Phosphorus control was superior in the DHD
group (% change from baseline to end-of-study 27730%
vsþ 7%735% in the CHD group, P¼ 0.0001). Percentage of
patients using phosphate binders decreased from 77 to 40%
among subjects on DHD, whereas these parameters did not
change (76 vs 77%) in the CHD group (P¼ 0.03 by
Breslow–Day test for homogeneity of the odds ratios). Weekly
mean phosphorus removal was higher in the DHD group
(24527720 mg/week vs 15727366 mg/week, P¼ 0.04).
Mean normalized protein catabolic rate increased
(0.9070.43–1.2270.26 g/kg/day, P¼ 0.0013). DHD was also
associated with an increase in the percent of subjects
achieving three or more mineral metabolism goals (for
phosphorus, calciumphosphorus and parathyroid
hormone) (15 vs 46%, P¼ 0.046). In conclusion, DHD
improves phosphorus control by increasing dialytic
phosphorus removal while maintaining nutritional status and
reducing the use of phosphate binders. The net effect allows
for improved achievement of mineral metabolism goals.
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The contribution of abnormalities in mineral metabolism to
all-cause and cardiovascular mortality in the setting of
chronic kidney disease has been receiving increasing atten-
tion. Hyperphosphatemia in particular has been indepen-
dently associated with death in patients receiving
maintenance hemodialysis (HD).1–4 Despite a concerted
effort by the nephrology community to standardize target
ranges for metabolic control, hyperphosphatemia remains a
significant problem among conventional hemodialysis
(CHD) patients.
With mortality among HD patients still unacceptably
high, interest has increased in the potential advantages
of more intensive, quotidian dialysis strategies including
daily hemodialysis (DHD) and nocturnal HD. More intensive
HD therapies have been associated with improvements
in surrogate cardiovascular endpoints such as left ventricular
mass and other intermediate outcomes;5–15 however,
reports on the effects of DHD on control of mineral
metabolism have been mixed.10,13,16–22 It is conceivable
that ‘short daily’ dialysis (i.e., 2.0–2.5 h six times per week),
might improve phosphorus control over conventional three
times per week dialysis by enhancing phosphorus removal, as
the removal of phosphorus is likely to be greatest early in the
dialysis session, although the kinetics of phosphorus removal
appear more complex than for non-charged, small solutes,
such as urea.23 In clinical studies, DHD provided for fewer
than 3 h has not been consistently shown to effectively
control serum phosphorus.17,21,22 Two more recently com-
pleted studies have shown that DHD (six times per week)
with a session length of 3 h can improve phosphorus
control.24,25
We hypothesized that DHD with a modest session length
(3 h) by augmenting phosphorus removal relative to CHD
would improve mineral metabolism. To address these
questions, we analyzed data from a prospective, controlled
study to determine the effects of DHD on control of
phosphorus and to assess the relative and potentially
competing effects of diet and dialysance on phosphorus
control we directly measured weekly phosphorus removal in
a subset (n¼ 10) of study subjects.
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RESULTS
Baseline characteristics
There were no deaths and no dropouts during the 12-month
study period. Table 1 shows baseline characteristics among
subjects assigned to DHD and subjects assigned to CHD.
There were no significant differences in case mix (age, sex,
race, diabetes, and vintage), comorbidity, vascular access, and
most laboratory studies. Subjects in the DHD group had
lower mean serum calcium (8.4 vs 9.0 mg/dl, P¼ 0.0005)
higher mean serum phosphorus (6.3 vs 5.0 mg/dl,
P¼ 0.0006) and calcium phosphorus product concentra-
tions (52.5 vs 44.8 mg2/dl2, P¼ 0.04), and lower hemoglobin
concentrations (10.8 vs 12.7 g/dl, P¼ 0.01) (Table 1). In
the subset of patients in whom weekly phosphorus removal
was quantified, there was no significant difference in the
predialysis phosphorus between the DHD and CHD groups
(4.1 vs 4.5 mg/dl, P¼ 0.75).
Phosphorus control and use of phosphate binders
The mean serum phosphorus was significantly lower in
DHD-treated subjects than in CHD subjects at 12-month
follow-up (4.20 vs 5.02 mg/dl, Po0.0001) (Figure 1a). The
percentage change in serum phosphorus from baseline to
end-of-study was –27730% (6.26–4.20 mg/dl) in the DHD
group (Figure 1a), whereas there was no change in the serum
phosphorus in the CHD group (Figure 1a). In the entire
study population, in the DHD group, the percent of subjects
using phosphate binders (either calcium acetate or sevelamer
hydrochloride) decreased from 77 to 40% (P¼ 0.01) whereas
there was no change in the percent of patients taking
Table 1 | Demographic characteristics and baseline clinical and laboratory information among patients assigned to DHD vs
CHD
DHD (n=26) CHD (n=51) P-value
Age (year) 51711.7 5478.5 0.48
Women 9 (35) 17 (33) 0.91
Ethnicity
White 1 (4) 0 (0) 0.69
Hispanic 24 (92) 47 (92)
Black 1 (4) 3 (6)
Other 0 (0) 1 (2)
Etiology of kidney diseasea
Diabetes mellitus 20 (77) 35 (67) 0.45
Hypertension 25 (96) 51 (100) 0.34
Polycystic kidney disease 1 (4) 1 (2) 1.00
Glomerulonephritis or vasculitis 3 (12) 7 (14) 1.00
Unknown 5 (7) 6 (12) 0.38
Khan risk groups
Low 0 (0.0) 0.0
Moderate 7 (27) 16 (31)
High 19 (73) 35 (69) 0.69
Vascular access
Catheter 4 (15) 4 (8) 0.43
Arteriovenous fistula 14 (55) 26 (51) 0.30
Arteriovenous graft 8 (30) 21 (41) 0.16
History of smoking 11 (42) 23 (45) 0.81
Duration of dialysis (year) 2.8172.98 3.8772.97 0.14
Hospitalization (days/year) 4.3878.57 5.3779.18 0.51
Laboratory values
Serum calcium (mg/dl) 8.3571.26 9.0170.70 0.0005
Serum phosphorus (mg/dl) 6.2672.57 4.9871.49 0.0006
Calciumphosphorus 52.5723.0 44.8713.2 0.0385
Hemoglobin (g/dl) 10.871.93 12.771.31 o0.0001
Parathyroid hormone (pg/ml) 451 (228,879) 535 (311,854) 0.76
C-reactive protein (mg/dl) 1.1 (0.6, 2.2) 0.6 (0.3, 1.2) 0.68
Serum albumin (mg/dl) 3.9670.40 4.0670.26 0.12
Homocysteine (mmol/l) 15.2 (12.2, 20.5) 19.7 (15.8,22.8) 0.21
Total cholesterol (mg/dl) 171742.4 173761.1 0.70
Triglycerides (mg/dl) 155769.4 1877197 0.18
Glucose (mg/dl) 132774.4 147767.6 0.38
CHD, conventional hemodialysis; DHD, daily hemodialysis.
Note: Values expressed as mean7s.d., median (interquartile range) or proportions.
aThere may be more than one etiology of kidney disease.
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phosphate binders in the CHD group (76–77%, P¼ 0.94 for
CHD and P¼ 0.03 for between group). The use of calcium
acetate in the DHD group decreased from 68 to 16%
(P¼ 0.0015) (Figure 1b) and the use of sevelamer decreased
from 48 to 24% (P¼ 0.023) (Figure 1c). In the daily dialysis
group, among patients taking phosphate binders, median
dose of calcium acetate decreased from 6.2 (3.1, 9.3) to 2.2
(1.0, 8.6) tablets/day and the median dose of sevelamer was
unchanged from baseline to follow-up. In the conventional
dialysis group there was no change in the dose of either
calcium acetate or sevelamer from baseline to follow-up.
Phosphate removal
The total weekly phosphorus removal was 56% greater in the
DHD group than in the CHD group (24527720 vs
15727366 mg, P¼ 0.04) (Figure 2). In the DHD group, the
rate of phosphorus removal was significantly greater in the
first hour of dialysis than in the third hour of dialysis
(178752 vs 107727 mg, P¼ 0.008) (Figure 3). In the CHD
group, the rate of phosphorus removal was significantly
higher in the first hour of dialysis (195770 mg) than in the
second (125733 mg, P¼ 0.01), third (107725 mg,
P¼ 0.001), and fourth (97720 mg, P¼ 0.0003) hours of
dialysis (Figure 3). There were no significant differences in
the rates of hourly phosphorus removal between the DHD
and CHD groups for the first, second and third hours of
dialysis (Figure 3). If only the first 2 h of dialysis were
considered in the DHD group, weekly phosphorus removal
would have been approximately 1809 mg in the DHD group,
which was not significantly different from the CHD group
(P¼ 0.90).
Dialysis adequacy
Urea reduction ratio was decreased in the DHD group
(71.2712.3 to 64.5710.1, Po0.001) whereas urea reduction
ratio increased in the CHD group (72.979.15 to 78.975.83,
Po0.001). Hemoglobin increased in the DHD group
(10.871.93 to 12.771.00, Po0.0001), whereas hemoglobin
did not change in the conventional dialysis group (12.771.31
to 12.070.7).
Achievement of mineral metabolism goals
In the DHD group, there was an increase from 15 to 46%
(P¼ 0.046) in the proportion of subjects who achieved three
or more mineral metabolism targets at follow-up, whereas in
the CHD group there was no significant change in the
percentage of patients who achieved 3 or more mineral
metabolism targets (P¼ 0.08 by Breslow–Day test for
homogeneity) (Figure 4). The fraction of subjects who
reached mineral metabolism targets for phosphorus, calcium,
and parathyroid hormone were higher among DHD-treated
subjects, although the proportional changes were not
statistically significant.
Nutritional markers
In the entire study population, among the DHD group, we
observed a significant increase in normalized protein
catabolic rate (nPCR) from baseline to end-of-study
(0.9070.43 to 1.2270.26 g/kg/day, P¼ 0.0013) (Figure 5).
By contrast, there was no change in nPCR in the CHD group
(Figure 5).
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Figure 1 | Phosphorus control and use of phosphate binders.
(a) Phosphorus control in DHD group. *Po0.0001 Baseline DHD vs
baseline CHD. ** Po0.0001 12-month follow-up DHD vs 12-month
follow-up conventional dialysis. baseline. (b) Use of calcium acetate.
***Po0.01 DHD baseline vs 12-month follow-up. (c) Use of
sevelamer. *Po0.05 DHD baseline vs 12-month follow-up.
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Figure 2 | Total weekly phosphorus removal. *P¼ 0.04 daily dialysis
vs conventional dialysis.
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Figure 3 | Hourly phosphorus removal in DHD vs CHD. *For
intragroup comparison DHD first hour vs DHD third hour (P¼ 0.008),
**For intragroup comparison: CHD first hour vs CHD second hour
(P¼ 0.01), CHD third hour (P¼ 0.001), and CHD fourth hour
(P¼ 0.0003).
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DISCUSSION
Herein we report that receipt of DHD with a session length of
3 h is associated with improved phosphorus control which
can be achieved despite an increase in dietary protein intake
(as approximated by nPCR), owing to an increase in
phosphorus removal, the net effects of which are to control
serum phosphorus while maintaining nutritional status.
Previous studies examining the effect of DHD on mineral
metabolism have reported mixed results.10,13,16–20 The lack of
efficacy of ‘short’ DHD in improving mineral metabolism
reported by previous investigators may have resulted from
diminished phosphorus clearance in 2.0–2.5 h per session as
compared with 3.0 h here, or could be explained by
confounding by dietary intake. Previous investiga-
tors19,20,26,27 employing DHD with short session length
protocols have shown improved nutritional status in some
cases, but the net effects on phosphorus balance were not
always favorable. In this study, the weekly phosphorus
removal in the first 2 h of dialysis in the DHD group
exceeded removal in the conventional group by 237 mg. This
small incremental increase in phosphorus removal is not
likely to be sufficient to offset the increased protein intake,
shown by increased nPCR in association with DHD.19,26,27
This is the first study to our knowledge to directly measure
dialytic phosphorus removal over an entire week in both
daily dialysis and conventional dialysis groups (Figure 2) and
demonstrates why shorter session (2 h) daily dialysis regi-
mens have not been shown to consistently improve
phosphorus control. Our daily dialysis group employed a
session length of 3 h and this resulted in improved
phosphorus removal over CHD (Figure 2). As a result of
this increased dialytic phosphorus removal in the DHD
group (Figure 2), improved phosphorus control was achieved
while simultaneously reducing the use of phosphate binders
(Figure 1) and increasing protein intake as reflected by
increased normal protein catabolic rate (Figure 5).
We also report that CHD removed only 1574 mg of
phosphorus per week (Figure 2). Our study underscores the
importance of direct measurements of phosphorus removal
as the actual phosphorus removal we observed was
significantly less than other investigators had predicted based
upon extrapolation from single session phosphorus removal
values28 and is lower than the amount of phosphorus
removal (3007 mg/week) observed by Vaithilingam et al.29 in
4 h CHD. Many studies have previously quantified dialytic
phosphorus removal28,30–38 though our study is the first to
our knowledge to measure phosphorus removal in DHD and
CHD over an entire week of dialysis. Conventional dialysis
therapy is efficacious at removing phosphorus at relatively
higher levels of predialysis serum phosphorus. This is because
the most consistent predictor of phosphorus removal during
dialysis is the predialysis phosphorus level.39 When the
predialysis phosphorus exceeds 6.0 mg/dl, a 4-h dialysis
session has been reported to remove between 1026 and
1190 mg.28,31,34,37 However, at lower serum phosphorus
levels, the efficacy of a 4 h CHD session at phosphorus
removal decreases. When the predialysis phosphorus is
o5.0 mg/dl, a 4-h session has been reported to remove
between 404 and 533 mg.30,36,38 Therefore our results are
consistent with these previous studies and the discrepancy
between our results and previous predictions of phosphorus
removal with DHD28 and measured weekly phosphorus
removal with CHD,29 may be due to the lower serum
phosphorus concentrations observed among subjects in the
present study. Furthermore, our results illustrate the point
that HD is relatively inefficient at removing phosphorus
where levels of serum phosphorus are between 4.0 and
4.5 mg/dl.
Finally, our study demonstrates that in patients with poor
mineral metabolism, DHD of 3 h, six times per week,
through improved phosphorus control can improve attain-
ment of multiple mineral metabolism goals (Figure 4). In our
study, however, the percent achievement of mineral metabo-
lism goals was similar in the DHD and CHD groups,
therefore our results may only be relevant to patients with
poor mineral metabolism control. The simultaneous achieve-
ment of multiple mineral metabolism goals is an area that
needs improvement as CHD patients rarely meet all four
mineral metabolism goals simultaneously.40 Given mixed
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results of daily dialysis on mineral metabolism control with
shorter 1.5–2.5 h protocols,19,20,26,27 our study suggests that
mineral metabolism improvements may be attained with in-
center DHD with longer (3 h) session lengths. Further studies
with larger numbers of patients and a randomized study
design, in which both dialysis time and frequency are
increased, will ultimately be necessary to determine if in-
center DHD is the optimal treatment for poor mineral
metabolism control.
This study has several strengths. Among studies of DHD,
the sample size is relatively large and follow-up time relatively
long with no patient dropouts. There are also several
important limitations. The trial was non-randomized with
an open-label design. Therefore, the study was susceptible to
confounding owing to baseline differences in clinical
characteristics and potential differences in co-interventions
such as phosphate binders and active vitamin D derivatives,
which may affect mineral metabolism and cardiovascular
outcomes.41 However, the baseline risk profile vis-a`-vis
mineral metabolism was worse among subjects assigned to
DHD, and the improved control of phosphorus in the DHD
group cannot be explained by an increased use of binders
and/or a decrease in dietary protein intake. On the contrary,
subjects on DHD used fewer phosphate binders and
exhibited a significant increase in nPCR, a valid surrogate
of dietary protein intake. The dialysis population in San
Antonio is disproportionately Hispanic (Mexican American),
so that the findings described here may not be fully
generalizable to the entire HD population in the United
States.
In conclusion, we found that DHD was associated with
improved control of serum phosphorus and improved
dialytic phosphorus removal. Furthermore, we provide
empiric evidence for why short session (2 h) DHD has not
consistently been shown to improve phosphorus control
compared with 4 h, thrice weekly dialysis. Given the
associations among parameters of mineral metabolism,
mortality and morbidity in end-stage renal disease, multiple
methods of improving control of mineral metabolism should
now be considered, including the provision of phosphate
binders and agents that can attenuate the downstream effects
of secondary hyperparathyroidism. DHD should be consid-
ered when disorders of mineral metabolism cannot be
controlled by conventional means. A randomized, controlled
clinical trial will ultimately be required to confirm or refute
the findings related to the effects of daily vs CHD on
parameters of mineral metabolism.
MATERIALS AND METHODS
Study participants
As previously described,24 study subjects were adults undergoing
outpatient HD at Dialysis West at the Texas Diabetes Institute, San
Antonio, TX, USA during 2003. The Bexar County Hospital District
approved the prospective enrollment of 26 individuals in a DHD
program over 12 months. All prevalent dialysis patients at Dialysis
West were considered eligible. One hundred and eight individuals
were screened for enrollment and DHD was offered to all 108; no
patient was excluded for clinical or other criteria.
Thirty-six patients agreed to participate and spaces were offered
on a voluntary basis until 26 subjects were enrolled. A control group
of 51 contemporary CHD patients from the original 108 study
eligible patients was selected (roughly balanced on age, sex, etiology
of chronic kidney disease, comorbidity, vascular access, medications,
and dialysis vintage). The study protocol was approved by the
University of Texas Health Sciences Center Institutional Review
Board and all subjects provided written informed consent.
Study design
The study was a 12-month, prospective, non-randomized, con-
trolled study of DHD (six sessions per week of 3 h each) vs CHD
(three sessions per week of 4 h each). Both treatments groups used
non-reuse, polysulfone, high flux dialyzers (Optiflux 2000, Frese-
nius); prescribed blood and dialysate flow rates were 400 ml per min
and 800 ml per min, respectively. Other than the dialysis prescrip-
tion, other care decisions, including medication use, were at the
discretion of the treating nephrologists. Calcium acetate was
prescribed in 667 mg tablets and sevelamer prescribed in 800 mg
tablets three times a day before meals. Generally, other elements of
dialysis- and kidney disease-related care were provided according to
clinical practice guidelines from the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative (K/DOQI).42 All
subjects were dialyzed on a 2.5 meq/l calcium bath, with individua-
lized dialysate sodium, potassium and bicarbonate concentrations.
All subjects in whom there were no conventional contraindications
were treated with low-dose (81 mg per day) aspirin, 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (‘statins’) and
angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers. At baseline, subjects were stratified into three categories
according to age, diabetes and pre-existing comorbidities as defined
by Khan et al.43,44
Quantification of dialytic phosphorus removal
Ten subjects (five in each of the DHD and CHD groups) were
randomly selected to participate in a substudy quantifying
phosphorus dialysance. During a 2-week period, effluent dialysate
was collected during each hour of dialysis for 1 week for each
subject. Effluent dialysate volume was measured for each hour of
dialysis and an aliquot of dialysate was taken from each hourly
collection. Samples were frozen at 201C immediately following
collection. Phosphorus concentrations were measured on all
dialysate samples in a single batch upon the completion of sample
collection. Before collecting dialysate samples, the stability of
phosphorus concentrations during sample storage was verified by
collecting parallel test specimens and running them fresh and after 1
week of storage at 201C. On each day of dialysate collection,
control specimens of post-dialyzer effluent dialysate were collected
before initiating HD from one of the study subjects and these
specimens had undetectable phosphorus concentrations.
Laboratory measurements
Serum phosphorus (normal range, 2.4–4.6 mg/dl) and calcium
(normal range 8.2–10.0 mg/dl) were measured by colorimetric
methods. Intact parathyroid hormone was measured by chemilu-
minescence (normal range, 11–67 pg/ml). Laboratory tests were
measured predialysis mid-week (i.e., on a Wednesday or Thursday).
Baseline laboratory studies were values averaged over the 3 months.
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Dialysate phosphorus concentrations were measured by colorimetric
methods using an Olympus AU400 analyzer, in triplicate in a single
session, with sample volume doubled to concentrate the specimen so
that concentrations were within the linearity range of the
instrument.32
Outcome measures
Outcome measures included the proportion of subjects in each
group achieving mineral metabolism goals for phosphorus, calcium,
calcium phosphorus product, and parathyroid hormone42 at
baseline and at 12-month follow-up. Among the 10 subjects who
participated in the substudy on phosphorus removal, we compared
weekly phosphorus removal between the two groups.
Statistical analysis
The percent of subjects achieving goals for mineral metabolism were
compared with the w2 or Fisher’s Exact test. The comparisons of
achieving multiple mineral metabolism targets at 12-month follow-
up were examined by Mantel–Haenszel modified ridit score.
Homogeneity of the odds ratio between groups were evaluated by
the use of the Breslow–Day test. Changes in mean laboratory values
(baseline to end-of-study), phosphorus removal, and nPCR between
the DHD and CHD groups were compared with Student’s t-test or
the Wilcoxon rank sum test. Two-sided Po0.05 were considered
significant. All statistical analyses were performed with SAS
statistical software, version 9.1 (Cary, NC, USA).
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